ArticleJournal of clinical laboratory analysis2000
Detection of specific antibody isotypes and subtypes before and after treatment of American visceral leishmaniasis.
Article in Journal of clinical laboratory analysis, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 42 citations in OpenAlex.
- Detection of anti-leishmania (Leishmania) chagasi immunoglobulin G by flow cytometry for cure assessment following chemotherapeutic treatment of American visceral leishmaniasis.Clinical and vaccine immunology : CVI · 2007Trial
- Gene Signatures of Symptomatic and Asymptomatic Clinical-Immunological Profiles of Human Infection byMicroorganisms · 2023Article
- Article
- Article
- Regulation of immunity during visceral Leishmania infection.Parasites & vectors · 2016Review
- Natural Mosquito-Pathogen Hybrid IgG4 Antibodies in Vector-Borne Diseases: A Hypothesis.Frontiers in immunology · 2016Article
- In vitro activity and in vivo efficacy of a combination therapy of diminazene and chloroquine against murine visceral leishmaniasis.Journal of biomedical research · 2015Review
- Article
- Serological and infection statuses of dogs from a visceral leishmaniasis-endemic area.Revista de saude publica · 2014Article
- Significance of persistence of antibodies against Leishmania infantum in Sicilian patients affected by acute visceral leishmaniasis.Clinical and experimental medicine · 2012Article
- Vaccine Development Against Leishmania donovani.Frontiers in immunology · 2012Article
- Immunobiology of visceral leishmaniasis.Frontiers in immunology · 2012Article
- Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis.Journal of clinical microbiology · 2005Article
- Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy.Infection and immunity · 2004Article
- Elevated TGF-beta levels in drug-resistant visceral leishmaniasis.Annals of Saudi medicineArticle
- The Emergence of Co-Infection of Visceral Leishmaniasis in an Iranian Child with Chronic Granulomatous Disease: A Case Report.Iranian journal of parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sera from patients with American visceral leishmaniasis (AVL) were studied before and after treatment based on their antibody isotypes and subtypes. The study was comprised of 33 Brazilian patients with well-defined diagnosis of AVL and 39 clinically healthy individuals. Antileishmanial antibody isotypes and subtypes were observed in almost all patients, except IgA that was detected in about 63% of them. The sensitivity and specificity of the immunofluorescence assay in the detection of antibody isotypes (IgG and IgM) and subtypes (IgG1, IgG2, IgG3, and IgG4) were high with no statistical difference, ranging from 0.937 to 1.000 and from 0.954 to 1.000, respectively. All IgG antibodies and its subtypes had their levels reduced after treatment. However, the IgG4 had an early decay and its conversion to negative was significantly high in children. Moreover, the profile of IgG4 before treatment corresponded to a unimodal curve that shifted to a patent bimodal curve after treatment, indicative of therapeutic success. Thus, the IgG4 shows to be a suitable immunological marker for the assessment of chemotherapy in AVL patients or communities. Our findings suggest that IgG4 correlates with IL-4 that also decreases after therapy.
Indexed as
Identifiers
10645978PMC6807925W2091507885What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.